Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer (DEEM)

Diet, Exercise and Estrogen Metabolites Study (DEEM)

This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer. Studying the effects that changes to daily eating and exercise habits can have on the body's hormone levels and the body's ability to activate proteins may help doctors identify interventions for individuals at high risk for breast cancer.

Study Overview

• Status: Completed
• Conditions: Ductal Breast Carcinoma in Situ; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Atypical Ductal Breast Hyperplasia; Lobular Breast Carcinoma in Situ; Atypical Lobular Breast Hyperplasia
• Intervention / Treatment: Other: laboratory biomarker analysis; Other: questionnaire administration; Other: counseling intervention; Behavioral: behavioral dietary intervention; Behavioral: exercise intervention

Detailed Description

PRIMARY OBJECTIVES:

I. To calculate eligibility rates, participation rates, retention, and adherence within the Diet, Exercise and Estrogen Metabolites (DEEM) study.

II. To determine inter- and intra-person variability of the estrogen-deoxyribonucleic acid (DNA) adducts (EDA) biomarkers in participants of the DFS.

III. To explore the effects of the intervention on percent adiposity and the EDA ratio at the end of the 3-month intervention and 6-month follow-up.

SECONDARY OBJECTIVES:

I. To explore the effects of the intervention on the DNA damage repair (DDR) biomarker at 3-months.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I: Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.

ARM II: Participants receive their usual care and are also provided with study materials on healthy diet and exercise at the end of the study.

After completion of study, participants are followed up for 3 months.

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Women will be considered at high risk for developing breast cancer if they fulfill one of the following criteria:

  • A Gail model risk of >= 1.7% over 5
  • Claus model lifetime risk of > 20%
  • Tyrer-Cuzick model lifetime risk > 20%
  • Personal history of breast biopsy showing atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS)
  • Ductal carcinoma in situ (DCIS) that has been previously treated; patients must be at least 2 months from completion of primary therapy not currently on hormonal therapy
  • Deleterious mutation in breast cancer (BRCA)1 or BRCA2 another gene known to increase the risk of developing breast cancer
  • Risk assessment of 20% chance or greater of carrying a BRCA1/2 gene mutation; the BRCAPRO model will be used to assess this risk

• Body mass index (BMI)

  • For postmenopausal women: a BMI of > 28 and < 40
  • For premenopausal women: a BMI of > 25 and < 40
• Willingness to provide informed consent
• Physically able to undertake a moderate exercise program (assessed at the clinic visit)
• Participant has the ability to attend weekly group counseling sessions and subsequent clinic visits
• Participant has the ability to communicate in English
• Participant agrees to be randomly assigned

Exclusion Criteria:

• Women who are currently engaged in more than 90 min of moderate to vigorous exercise per week at the time of recruitment
• Alcohol/drug abuse or significant mental illness, as assessed by study personnel
• Previous diagnosis of invasive cancer within the past 5 years (in situ breast cancer and simple basal or squamous cell carcinoma not included)
• Plans to leave the geographic area within six months
• Contraindications for treadmill testing or entry into a training program
• Pregnant women or women planning to be pregnant in the following year will not be admitted in to the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Arm I (DEEM intervention); Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.	Other: laboratory biomarker analysis; Correlative studies; Other: questionnaire administration; Ancillary studies; Other: counseling intervention; Take part in weekly group counseling sessions; Other Names: counseling and communications studies; Behavioral: behavioral dietary intervention; Set goals for changing dietary habits; Behavioral: exercise intervention; Attend group exercise activities
NO_INTERVENTION: Arm II (usual care); Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Level of adherence to the dietary component evaluated using the 3-day food records	Descriptive statistics will be calculated. The percentage of women meeting the study's eligibility criteria, percentage of those who agree to participate, and the percentage of those who complete the study will be stratified by intervention group. This analysis will summarize data collected from the participants' into themes.	Up to 9 months
Level of adherence to the exercise component evaluated using the physical activity logs	Descriptive statistics will be calculated. The percentage of women meeting the study's eligibility criteria, percentage of those who agree to participate, and the percentage of those who complete the study will be stratified by intervention group. This analysis will summarize data collected from the participants' into themes.	Up to 9 months
Level of adherence to the group counseling sessions component evaluated by tracking attendance	Descriptive statistics will be calculated. The percentage of women meeting the study's eligibility criteria, percentage of those who agree to participate, and the percentage of those who complete the study will be stratified by intervention group. This analysis will summarize data collected from the participants' into themes.	Up to 9 months
Inter-person variability	The variance of the EDA biomarkers will be calculated in all participants at baseline, and stratify upon study arm. In order to determine the level of variance for biomarkers that is due to between-person variation in relation to the amount of variance that is due to within-person variance, the intra-class correlation coefficient will be calculated among the controls, which is based on the analysis of variance.	Up to 3 months
Change in EDA biomarker levels	Linear regression models will be used for correlated outcomes.	Baseline to up to 6 months
Change in BMI	Linear regression models will be used for correlated outcomes.	Baseline to up to 6 months
Change in percentage of total fat	Linear regression models will be used for correlated outcomes.	Baseline to up to 6 months
Change in percentage of body fat as measured by BMI	Linear regression models will be used for correlated outcomes.	Baseline to up to 6 months
Movement through the stages of change (pre-contemplation, contemplation, action, and maintenance) and data collected from quality of life questionnaires	The participant's baseline level of readiness for change modified the effect of the intervention will be investigated, with the hypothesis that the largest impact will be observed within those with the highest level of readiness for change.	Up to 9 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Differences in change of the DNA repair assay in intervention participants versus controls	Analysis of variance will be used.	Baseline to up to 3 months

Collaborators and Investigators

• Sponsor: University of Washington
• Collaborators: National Cancer Institute (NCI); National Institute of Nursing Research (NINR)
• Investigators: Principal Investigator: Kerryn Reding, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Publications and helpful links

General Publications

• Stone SA, Han CJ, Senn T, Korde LA, Allott K, Reding S, Whittington D, Reding KW. Sex Hormones in Women With Elevated Breast Cancer Risk Undergoing Weight Loss. West J Nurs Res. 2019 Nov;41(11):1602-1622. doi: 10.1177/0193945918820672. Epub 2019 Jan 7.

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (ACTUAL): April 1, 2015

Study Registration Dates

• First Submitted: June 6, 2013
• First Submitted That Met QC Criteria: June 7, 2013
• First Posted (ESTIMATE): June 10, 2013

Study Record Updates

• Last Update Posted (ESTIMATE): January 20, 2016
• Last Update Submitted That Met QC Criteria: January 15, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Skin Diseases; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Breast Diseases; Neoplasms, Ductal, Lobular, and Medullary; Carcinoma, Ductal; Carcinoma in Situ; Breast Neoplasms; Carcinoma; Hyperplasia; Breast Carcinoma In Situ; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Ductal, Breast
• Other Study ID Numbers: 9026 (CTEP); P30CA015704 (U.S. NIH Grant/Contract); NCI-2014-00929 (REGISTRY: CTRP (Clinical Trial Reporting Program)); 44358-J; R00NR012232 (NIH)